Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1987 Sep;25(2):105–110. doi: 10.1007/BF00199949

The generation of tumor-specific in vivo protective immunity in the tumor mass from mice rendered tolerant to tumor antigens

Shigetoshi Sano 1, Yutaka Izumi 1, Shigetaka Sugihara 1, Hiroto Nakajima 1, Hiromi Fujiwara 1,✉, Toshiyuki Hamaoka 1
PMCID: PMC11038216  PMID: 3499223

Abstract

C3H/He mice were inoculated i.v. with 106 heavily X-irradiated syngeneic X5563 plasmacytoma cells 3 times at 4 day intervals. When these mice received an appropriate immunization procedure consisting of i. d. inoculation of viable tumor cells plus the surgical resection of the tumor which enables i.v. nonpresensitized mice to produce anti-X5563 immunity, they failed to develop tumor-specific immunity. This was demonstrated by the abrogation in potential of spleen and lymph node cells to generate in vivo protective immunity. In contrast, the tumor mass from X5563 tumor-bearing mice which had received the i.v. presensitization contained comparable anti-X5563 tumor neutralizing activity to that obtained from the tumor mass from nonpresensitized, X5563 tumor-bearing mice. Such an in vivo protective immunity was revealed to be mediated by tumor-specific T cells. These results demonstrate the differential generation and antitumor capability of tumor infiltrating T cells and T cells in lymphoid organs from mice which are in the tumor-specific tolerant state. The results are discussed in the context of potential utilization of tumor infiltrating in vivo protective T cells to enhance the local tumor-specific immunity in tumor-specific tolerant mice.

Keywords: Lymph Node, Surgical Resection, Tumor Mass, Tumor Antigen, Potential Utilization

Footnotes

This work was supported by Special Project Research-Cancer Bioscience from the Ministry of Education, Science and Culture

References

  • 1.Buessow SC, Paul RD, Lopez DM. Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice. J Natl Cancer Inst. 1984;73:249. [PubMed] [Google Scholar]
  • 2.Fujimoto S, Greene MI, Sehon AA. Regulation of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing mice. J Immunol. 1976;116:791. [PubMed] [Google Scholar]
  • 3.Fujiwara H, Hamaoka T, Kitagawa M. Suppressive effect of pretreatment with X-irradiated tumor cells on the induction of syngeneic murine tumor system. I. Suppressive versus sensitizing effect on the same pretreatment in 2 tumor systems with different immune resaponses. Gann. 1978;69:793. [Google Scholar]
  • 4.Fujiwara H, Tsuchida T, Mizuochi T, Kohmo T, Hamaoka T. Suppressive effect of X-irradiated tumor cell presensitization on the induction of syngeneic tumor immunity. III. The mechanism of specific suppression in effector T cell clones against tumor-associated transplantation antigens. Gann. 1981;72:732. [PubMed] [Google Scholar]
  • 5.Fujiwara H, Aoki H, Yoshioka T, Tomita S, Ikegami R, Hamaoka T. Estanblishment of tumor-specific immunotherapy model utilizing TNP-reactive helper T cell activity and its application to autochthonous tumor system. J Immunol. 1984;133:509. [PubMed] [Google Scholar]
  • 6.Fujiawara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T. The role of tumor-specific lyt-1+2− T cells in eradicating tumor cells in vivo. I Lyt-1+2− T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. J Immunol. 1984;133:1671. [PubMed] [Google Scholar]
  • 7.Fujiwara H, Moriyama Y, Suda T, Tsuchida T, Shearer GM, Hamaoka T. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity which results in tumor regression. J Immunol. 1984;132:1517. [PubMed] [Google Scholar]
  • 8.Fujiwara H, Sato S, Kosugi A, Fukuzawa M, Hamaoka T. Studies on the recovery from tolerance to tumor antigens. I. Bone marrow cells from tolerant hosts are not rendered tolerant, but provide potentials to reconstitute tumor-specific effector T cell clones. Cancer Immunol Immunother. 1987;24:113. doi: 10.1007/BF00205587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Glaser M, Herberman RB, Kirchner H, Djeu JY. Study of cellular immune response to Gross virus induced lymphoma by mixted lymphocyte-tumor cell interaction. Cancer Res. 1974;34:2165. [PubMed] [Google Scholar]
  • 10.Gorczynski RM. Evidence for in vivo protection against murine-sarcoma virus-induced tumors by T lymphocytes from immune animals. J Immunol. 1974;112:533. [PubMed] [Google Scholar]
  • 11.Hellstrom KE, Hellstrom I. Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol. 1974;18:209. doi: 10.1016/s0065-2776(08)60311-9. [DOI] [PubMed] [Google Scholar]
  • 12.Herberman RB, Holden HT, Varesio L, Taniyama T, Puccetti P, Kirchner H, Gerson J, White S, Keisari Y, Haskill JS. Immunologic reactivity of lymphoid cells in tumors. Contemp Top Immunobiol. 1980;10:61. doi: 10.1007/978-1-4684-3677-8_3. [DOI] [PubMed] [Google Scholar]
  • 13.Ibayashi Y, Ueda T, Ueda T, Kikuchi K. Functional analysis of mononuclear cells infiltrating into tumors: differential cytotoxicity of mononuclear cells from tumors of immune and nonimmune rats. J Immunol. 1985;134:648. [PubMed] [Google Scholar]
  • 14.Ishii Y, Matsuura A, Takami T, Ueda T, Ibayashi Y, Ueda T, Imamura M, Kikuchi K, Kikuchi Y. Lymphoid cell subpopulations infiltrating into autologous rat tumors undergoing rejection. Cancer Res. 1984;44:4053. [PubMed] [Google Scholar]
  • 15.Jones JA, Robinson G, Rees RC, Baldwin RW. Immune response of the draining and distal lymph nodes during the progressive growth of a chemically induced transplantable rat hepatoma. Int J Cancer. 1978;21:171. doi: 10.1002/ijc.2910210208. [DOI] [PubMed] [Google Scholar]
  • 16.Kamo I, Friedmen H. Immunosuppression and the role of suppressive factors in cancer. Adv Cancer Res. 1977;25:271. doi: 10.1016/s0065-230x(08)60636-3. [DOI] [PubMed] [Google Scholar]
  • 17.Kasahara T, Nakano K, Shioiri. Sugiura A. Detection of mitogen-activated T and non-T lymphocytes by virus plaque assay. Virus plaque assay on the cells fractionated by unit gravity sedimentation. Immunology. 1977;32:875. [PMC free article] [PubMed] [Google Scholar]
  • 18.Leclere JC, Cantor H. T cell-mediated immunity to oncornavirus-induced tumors. I. Ly phenotype of precursors and effector cytolytic T lymphocytes. J Immunol. 1980;124:846. [PubMed] [Google Scholar]
  • 19.Leclerc JC, Gomard E, Plata F, Levy JP. Cell-mediated reaction against tumors induced by oncornaviruses. II. Nature of the effector cells in tumor cell cytolysis. Int J Cancer. 1973;11:426. doi: 10.1002/ijc.2910110220. [DOI] [PubMed] [Google Scholar]
  • 20.Levy JP, Leclerc JC. The murine sarcoma virus-induced tumor: exception or general model in tumor immunology. Adv Cancer Res. 1977;24:1. doi: 10.1016/s0065-230x(08)61012-x. [DOI] [PubMed] [Google Scholar]
  • 21.Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  • 22.Russel SW, Doe WF, Hoskins RG, Cochrane CG. Inflammatory cells in solid murine neoplasms. I. Tumor disaggregation and identification of constituent inflammatory cells. Int J Cancer. 1976;18:322. doi: 10.1002/ijc.2910180309. [DOI] [PubMed] [Google Scholar]
  • 23.Tomita S, Fujiwara H, Yamane Y, Sano S, Nakajima H, Izumi Y, Arai H., Kawanishi Y, Tsuchida T, Hamaoka T. Demonstration of intratumoral infiltration of tumor-specific Lyt-1+2− T cells mediating delayed type-hypersensitivity response and in vivo protective immunity. Gann. 1986;77:182. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES